Natalizumab
Natalizumab (pronunciation: na-ta-li-zu-mab) is a monoclonal antibody used in the treatment of multiple sclerosis (MS) and Crohn's disease. It is marketed under the brand name Tysabri by Biogen.
Etymology
The name "Natalizumab" is derived from the Latin word "natalis" meaning "birth" and "zumab" is a suffix used in the names of humanized monoclonal antibodies.
Usage
Natalizumab is used primarily in the treatment of relapsing forms of multiple sclerosis and moderate-to-severe Crohn's disease. It works by preventing certain cells in the immune system from reaching the brain and spinal cord, thereby reducing inflammation and damage.
Administration
Natalizumab is administered by intravenous infusion, typically once every four weeks. The standard dose is 300 mg.
Side Effects
Common side effects of Natalizumab include headache, fatigue, joint pain, and allergic reactions. In rare cases, it can lead to a serious brain infection known as progressive multifocal leukoencephalopathy (PML).
Related Terms
- Monoclonal antibody
- Multiple sclerosis
- Crohn's disease
- Biogen
- Progressive multifocal leukoencephalopathy
See Also
- List of monoclonal antibodies
- List of drugs used in treatment of multiple sclerosis
- List of drugs used in treatment of Crohn's disease
External links
- Medical encyclopedia article on Natalizumab
- Wikipedia's article - Natalizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski